High anthracycline cumulative dose without cardiac toxicity: A possible protective role of morphine
To the Editor, Improvements in global anticancer strategy have resulted in better outcomes for a large proportion of cancer patients. Anthracyclines (A) are the best studied anticancer drugs with an established clinically significant dose-dependent cardiotoxicity. One of the strategies developed to reduce their well-known dose-dependent toxicity is dose limitation to 400-450 mg/m 2 for doxorubicin (DOX) and 900 mg/m 2 for epirubicin (E) (1). Preclinical evidences have pointed out a possible role for morphine as a cardioprotective agent (2, 3) . On the basis of these, we conducted a retrospective database search to determine patients receiving a higher E dose without cardiotoxicity so as to look for clinical or pharmacological protective factors while focusing on concomitant opioid use.
We collected data of patients who were receiving a cumulative dose of E >900 mg/m 2 (representing the threshold warning dose) and who had undergone regular appropriate cardiac monitoring (1) Excessive reactive oxygen species (ROS) generation by A, together with iron complexes formation, is the most accepted hypothesis on anthracycline-induced cardiomyopathy (4). Morphine can exert a cardioprotective role in preclinical models. Molecular mechanisms underlying the cardioprotective effect of morphine are poorly understood; however, a theory on prevention of ROS-induced cell apoptosis in neuroblastoma cells has proposed inhibition of ROS generation as well as blockade of nuclear factor-kappa B transcription signaling pathway by morphine (5). Morphine inhibits ROS generation and prevents DOX-mediated caspase-3 activation, cytochrome-c release, and changes in Bax and Bcl-2 protein expression, leading to inhibition of cell apoptosis (5). We found that all patients receiving higher than usual cumulative dose of E without cardiotoxicity concomitantly received long-term morphine treatment for pain control. Interestingly, when checked for concomitant "cardioprotective" medications (β-blockers, sartans, and RAAS inhibitors) to exclude possible confounding factors, none but two were found to have received such agents, making a protective effect unlikely .
Keeping in mind study limitations (small sample size, selection bias, single-center experience, and descriptive hypothesis-generating only comparison), our results represent the first clinical data supporting the preclinical hypothesis of a cardioprotective effect of morphine pretreatment. A prospective confirmation of our results on a larger population is needed.
